Pharmacokinetic and Metabolic Profile of Deutetrabenazine (TEV-50717) Compared With Tetrabenazine in Healthy Volunteers.

Clinical and Translational Science
Frank SchneiderLaura Rabinovich-Guilatt

Abstract

Deutetrabenazine (Austedo, Teva Pharmaceuticals) is a deuterated form of tetrabenazine. It is the first deuterated drug to receive US regulatory approval and is approved for treatment of chorea in Huntington's disease and tardive dyskinesia. Two oral single dose studies comparing deutetrabenazine (25 mg) with tetrabenazine (25 mg) in healthy volunteers evaluated the impact of deuteration on pharmacokinetics of the active metabolites, alpha-dihydrotetrabenazine (α-HTBZ) and beta-dihydrotetrabenazine (β-HTBZ), metabolite profile, safety, and tolerability. In the two-way, cross-over study, the mean elimination half-life of deuterated total (α + β)-HTBZ was doubled compared with nondeuterated total (α + β)-HTBZ, with a twofold increase in overall mean exposure (area under the concentration-time curve from zero to infinity (AUC0-inf )) and a marginal increase in mean peak plasma concentration (Cmax ). In the mass balance and metabolite profiling study, there were no novel plasma or urinary metabolites of [14 C]-deutetrabenazine relative to [14 C]-tetrabenazine. Specific deuteration in deutetrabenazine resulted in a superior pharmacokinetic profile and an increased ratio of active-to-inactive metabolites, attributes considered to pro...Continue Reading

References

May 1, 1966·Biochemical Pharmacology·D E SchwartzA Brossi
Mar 1, 1981·Clinical Pharmacology and Therapeutics·R A HamiltonB J Kline
Jul 1, 1981·Chemical & Pharmaceutical Bulletin·K Mimura, S Baba
Feb 3, 2007·Clinical Neuropharmacology·Marina de TommasoPaolo Livrea
Aug 6, 2011·The AAPS Journal·Leslie Z BenetTudor I Oprea
Dec 4, 2013·Journal of Medicinal Chemistry·Thomas G Gant
Jul 30, 2014·Expert Opinion on Therapeutic Patents·Graham S Timmins
Jul 6, 2016·JAMA : the Journal of the American Medical Association·UNKNOWN Huntington Study GroupEmily Christopher
Oct 11, 2016·Annals of Neurosciences·Navneet KaurVinod Gauttam
Apr 4, 2018·The Consultant Pharmacist : the Journal of the American Society of Consultant Pharmacists·Anne P KimTerri L Levien

❮ Previous
Next ❯

Citations

Oct 11, 2020·Clinical Pharmacology in Drug Development·Frank SchneiderLaura Rabinovich-Guilatt
Aug 10, 2021·Issues in Mental Health Nursing·Barbara WarrenJessica Johnson
Aug 19, 2021·Drug Metabolism Reviews·Siva Nageswara Rao GajulaRajesh Sonti

❮ Previous
Next ❯

Methods Mentioned

BETA
genotyping

Software Mentioned

SAS
Phoenix WinNonlin

Related Concepts

Related Feeds

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.